This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Astrazeneca Ab. Active years: 2011.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2011
Title: Jan Magnus Johansson: Innovator in Pharmaceutical Chemistry
Introduction
Jan Magnus Johansson is a notable inventor based in Mölndal, Sweden. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target specific biological pathways.
Latest Patents
Johansson holds a patent for "Carbamoyl compounds as DGAT1 inhibitors." This patent describes DGAT-1 inhibitor compounds of formula (I), along with pharmaceutically-acceptable salts and pro-drugs. These compounds are particularly relevant in the treatment of obesity, showcasing Johansson's commitment to addressing critical health issues.
Career Highlights
Johansson is associated with AstraZeneca AB, a leading global biopharmaceutical company. His work at AstraZeneca has allowed him to engage in cutting-edge research and development, contributing to innovative solutions in medicine.
Collaborations
Throughout his career, Johansson has collaborated with talented professionals, including Petra Johannesson and Annika Ulrika Petersson. These collaborations have enhanced the scope and impact of his research.
Conclusion
Jan Magnus Johansson is a distinguished inventor whose work in pharmaceutical chemistry has the potential to make a significant impact on health and wellness. His innovative approach to developing DGAT-1 inhibitors exemplifies the importance of research in combating obesity and related health challenges.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile